|Bid||0.00 x 29200|
|Ask||0.00 x 34100|
|Day's Range||39.91 - 40.39|
|52 Week Range||34.52 - 42.36|
|PE Ratio (TTM)||45.59|
|Forward Dividend & Yield||2.00 (5.14%)|
|1y Target Est||N/A|
Shire (SHPG) is a biotechnology company focused on the discovery, development, and commercialization of specialized medicines for the treatment of rare diseases and other specialized conditions.
GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
Let's see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Brussels threatens legal action against UK over customs ...
Nestle (NESN.S), Unilever (ULVR.L) (UNc.AS) and Coca-Cola (KO.N) are among bidders for GlaxoSmithKline's (GSK.L) Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said.
LONDON (Reuters) - GlaxoSmithKline (GSK.L) has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research ...
Nestle (NESN.S), Unilever (ULVR.L) (UNc.AS) and Coca-Cola (KO.N) are among bidders for GlaxoSmithKline's (GSK.L) Indian Horlicks nutrition business, expected to fetch more than $4 billion (3.03 billion pounds), four people familiar with the matter said. It was not clear which other companies were bidding, although Reckitt Benckiser (RB.L), a company eager to build up its consumer health operation, did not make an offer, two sources said. GSK, Nestle, Reckitt and Unilever declined to comment.
In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.
Some of the world’s biggest consumer companies have submitted non-binding bids for GlaxoSmithKline’s nutrition business as competition intensifies to secure the company’s prized Horlicks malted drink brand ahead of an auction later this year. is already bidding to buy Complan, a nutritional drink, from Kraft Heinz. Nestlé, Unilever and KKR declined to comment.
Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.
As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.
PHILADELPHIA (AP) — A Chinese scientist has pleaded guilty to conspiring to steal biopharmaceutical trade secrets from GlaxoSmithKline in what prosecutors said was a scheme to set up companies in China to market them.
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
On August 15, Johnson & Johnson (JNJ) and ViiV Healthcare, the HIV business subsidiary of GlaxoSmithKline (GSK), announced positive top-line results of their Phase 3 ATLAS (Antiretroviral Therapy as Long-Acting Suppression) trial. The regimen consists of Johnson & Johnson’s rilpivirine and ViiV Healthcare’s cabotegravir, which is injected once per month. The study evaluated this 2DR therapy with the standard of care three-drug daily oral regimen.
Johnson & Johnson (JNJ) is one of the major healthcare companies in the world. It operates through its pharmaceuticals, medical devices, and consumer business segments. Although its pharmaceutical business generates most of its sales, medical devices and consumer business include a number of leading brands in their respective market spaces.
Gilead executives talk about the future after reporting positive late-stage results for the company's experimental rheumatoid arthritis drug.
AstraZeneca’s (NYSE:AZN) profits look poised to resume growing, as a number of the drug company’s new treatments are expected to be approved by regulators. While ultimately the new drugs should compensate for the lost Crestor sales, it’s too early to say when the positive outlook will be reflected in AZN stock. If these forecasts hold, and AZN stock can trade consistently above $40 per share, AstraZeneca stock could finally rally.
FDA issues a complete response letter to Glaxo's (GSK) application for label expansion of its asthma drug, Nucala for COPD.
The Coca-Cola Co. is moving forward with its interest in GlaxoSmithKline Plc’s Indian malted milk drink company Horlicks Ltd, according to the Sunday Telegraph.